File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.lanwpc.2023.100745
- Scopus: eid_2-s2.0-85151440005
- WOS: WOS:001025922600001
Supplementary
- Citations:
- Appears in Collections:
Article: Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study
Title | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
---|---|
Authors | |
Keywords | Adverse events of special interest Covid-19 vaccines Myocarditis Pericarditis Vaccine safety |
Issue Date | 1-Jul-2023 |
Publisher | Elsevier Ltd. |
Citation | The Lancet Regional Health - Western Pacific, 2023, v. 35 How to Cite? |
Abstract | Background: Large-scale comparative research exploring the risk after the third dose and after inactivated covid-19 vaccination is limited. This study aimed to assess the risk of carditis following three doses of BNT162b2 or CoronaVac. Methods: We conducted a self-controlled case series (SCCS) and a case–control study using electronic health and vaccination records in Hong Kong. Carditis incidents within 28 days of covid-19 vaccination were included as cases. In the case–control study, up to 10 hospitalized controls were selected with stratified probability sampling by age, sex, and hospital admission (±1 day). The incidence rate ratios (IRRs) were reported from conditional Poisson regressions for SCCS, and adjusted odds ratios (ORs) were reported from multivariable logistic regressions. Findings: A total of 8,924,614 doses of BNT162b2 and 6,129,852 doses of CoronaVac were administered from February 2021 to March 2022. The SCCS detected increased carditis risks after BNT162b2: 4.48 (95%confidence interval [CI]:2.99–6.70] in 1–14 days and 2.50 (95%CI:1.43–4.38) in 15–28 days after first dose; 10.81 (95%CI:7.63–15.32) in 1–14 days and 2.95 (95%CI:1.82–4.78) in 15–28 days after second dose; 4.72 (95%CI:1.40–15.97) in 1–14 days after third dose. Consistent results were observed from the case–control study. Risks were specifically found in people aged below 30 years and males. No significant risk increase was observed after CoronaVac in all primary analyses. Interpretations: We detected increased carditis risks within 28 days after all three doses of BNT162b2 but the risk after the third doses were not higher than that of the second dose when compared with baseline period. Continuous monitoring of carditis after both mRNA and inactivated covid-19 vaccines is needed. Funding: : This study was funded by Hong Kong Health Bureau (COVID19F01). |
Persistent Identifier | http://hdl.handle.net/10722/337003 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fan, Min | - |
dc.contributor.author | Lai, Tsun Tsz Francisco | - |
dc.contributor.author | Cheng, Tak Wing Franco | - |
dc.contributor.author | Tsie, Ying Tsz Natalie | - |
dc.contributor.author | Li, Xue | - |
dc.contributor.author | Wan, Fai Yuk Eric | - |
dc.contributor.author | Wong, Ho King Carlos | - |
dc.contributor.author | Chan, Yin Wai Esther | - |
dc.contributor.author | Yiu, Hang Kai | - |
dc.contributor.author | Wong, Kei Chi Ian | - |
dc.contributor.author | Chui, Ling Sze Celine | - |
dc.date.accessioned | 2024-03-11T10:17:16Z | - |
dc.date.available | 2024-03-11T10:17:16Z | - |
dc.date.issued | 2023-07-01 | - |
dc.identifier.citation | The Lancet Regional Health - Western Pacific, 2023, v. 35 | - |
dc.identifier.uri | http://hdl.handle.net/10722/337003 | - |
dc.description.abstract | <p>Background: Large-scale comparative research exploring the risk after the third dose and after inactivated covid-19 vaccination is limited. This study aimed to assess the risk of carditis following three doses of BNT162b2 or CoronaVac. Methods: We conducted a self-controlled case series (SCCS) and a case–control study using electronic health and vaccination records in Hong Kong. Carditis incidents within 28 days of covid-19 vaccination were included as cases. In the case–control study, up to 10 hospitalized controls were selected with stratified probability sampling by age, sex, and hospital admission (±1 day). The incidence rate ratios (IRRs) were reported from conditional Poisson regressions for SCCS, and adjusted odds ratios (ORs) were reported from multivariable logistic regressions. Findings: A total of 8,924,614 doses of BNT162b2 and 6,129,852 doses of CoronaVac were administered from February 2021 to March 2022. The SCCS detected increased carditis risks after BNT162b2: 4.48 (95%confidence interval [CI]:2.99–6.70] in 1–14 days and 2.50 (95%CI:1.43–4.38) in 15–28 days after first dose; 10.81 (95%CI:7.63–15.32) in 1–14 days and 2.95 (95%CI:1.82–4.78) in 15–28 days after second dose; 4.72 (95%CI:1.40–15.97) in 1–14 days after third dose. Consistent results were observed from the case–control study. Risks were specifically found in people aged below 30 years and males. No significant risk increase was observed after CoronaVac in all primary analyses. Interpretations: We detected increased carditis risks within 28 days after all three doses of BNT162b2 but the risk after the third doses were not higher than that of the second dose when compared with baseline period. Continuous monitoring of carditis after both mRNA and inactivated covid-19 vaccines is needed. Funding: : This study was funded by Hong Kong Health Bureau (COVID19F01).</p> | - |
dc.language | eng | - |
dc.publisher | Elsevier Ltd. | - |
dc.relation.ispartof | The Lancet Regional Health - Western Pacific | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Adverse events of special interest | - |
dc.subject | Covid-19 vaccines | - |
dc.subject | Myocarditis | - |
dc.subject | Pericarditis | - |
dc.subject | Vaccine safety | - |
dc.title | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.lanwpc.2023.100745 | - |
dc.identifier.scopus | eid_2-s2.0-85151440005 | - |
dc.identifier.volume | 35 | - |
dc.identifier.eissn | 2666-6065 | - |
dc.identifier.isi | WOS:001025922600001 | - |
dc.identifier.issnl | 2666-6065 | - |